Hospices Civils De Lyon
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment - Therapeutics
Research at Hospices Civils De Lyon focuses on innovative diagnostic tools and therapeutic devices to enhance patient care across multiple conditions.
- Development of imaging biomarkers for skin diseases
- Validation of point‑of‑care testing for metabolic markers
- Integration of AI‑driven analysis in trial monitoring
- Assessment of novel delivery systems for topical agents
Thirty‑one investigators collaborate within fourteen active studies to bring these technologies to clinical use.
Bacterial Infections and Mycoses
Trials evaluate new antimicrobial strategies and supportive therapies to combat hospital‑acquired infections.
- Adjunctive immunotherapy for ventilator‑acquired pneumonia
- Optimization of antibiotic stewardship protocols
- Antifungal prophylaxis in immunocompromised patients
- Rapid diagnostic assays for bacterial pathogens
The department leverages intensive‑care expertise to improve outcomes for infected patients.
Cardiovascular Diseases
Research aims to refine cardiovascular risk management and antithrombotic regimens for high‑risk groups.
- Full‑dose anticoagulation versus combined therapy in acute venous thromboembolism
- Diuretic‑based algorithms for uncontrolled hypertension in chronic kidney disease
- Reduction of cardiovascular events in trial participants
- Long‑term safety of novel antiplatelet agents
A multidisciplinary team integrates cardiology insights to address overlapping renal and vascular conditions.
Immune System Diseases
Studies investigate immune‑modulating treatments to control autoimmune skin and systemic disorders.
- Novel biologics for cutaneous lupus erythematosus
- Targeted therapy for hidradenitis suppurativa
- Interferon‑gamma effects on immune response in critical care
- Long‑term safety monitoring of immune‑targeted agents
The dermatology unit at Hospices Civils De Lyon provides dedicated support for these immune‑focused investigations.
Male Urogenital Diseases
Clinical work explores androgen deprivation strategies and novel hormonal agents to improve prostate cancer outcomes.
- Combination of apalutamide with androgen deprivation therapy
- Imaging‑guided treatment planning using PSMA PET
- Pathological complete response rates after surgery
- Metastasis‑free survival assessment
Oncology collaboration within the site supports comprehensive research in high‑risk localized or locally advanced prostate cancer.
Neoplasms
Trials target solid tumors with innovative immunotherapy and targeted drug combinations.
- Pembrolizumab plus experimental agents for HPV‑positive head and neck carcinoma
- Checkpoint inhibitors in metastatic settings
- Biomarker‑driven patient selection
- Evaluation of treatment durability and survival outcomes
Multicenter coordination ensures robust data collection across oncologic studies.
Nutritional and Metabolic Diseases
Research focuses on metabolic correction and disease‑modifying therapies for rare inherited disorders.
- Lumasiran impact on plasma oxalate in primary hyperoxaluria type 1
- Encaleret effects on calcium homeostasis in autosomal dominant hypocalcemia
- Furosemide protocol to enhance stone‑free rates after ureteroscopy
- Monitoring of metabolic parameters in trial cohorts
Specialized metabolic laboratories support precise measurement of treatment effects.
Respiratory Tract Diseases
Investigations assess adjunctive treatments to shorten ventilation time and improve pulmonary outcomes.
- Recombinant interferon‑gamma for ventilator‑acquired pneumonia
- Anti‑inflammatory agents to reduce lung injury
- Advanced respiratory function monitoring tools
- Strategies to reduce intensive‑care unit length of stay
The respiratory team collaborates closely with intensive‑care specialists at the site.
Skin and Connective Tissue Diseases
A robust portfolio addresses severe inflammatory skin conditions through novel biologics and therapeutic algorithms.
- Spesolimab efficacy in moderate to severe hidradenitis suppurativa
- Vilobelimab for ulcerative pyoderma gangrenosum
- Litifilimab safety in active cutaneous lupus erythematosus
- Development of personalized treatment pathways for refractory skin disease
The dermatology department at Hospices Civils De Lyon leads these patient‑centered studies.
Psychiatry and Psychology - Behavioral Disciplines and Activities
Studies aim to improve substance‑use management and mental health outcomes through behavioral interventions and pharmacologic support.
- Baclofen for benzodiazepine tapering in dependence
- Evaluation of addiction counseling models
- Assessment of mental health scales in trial participants
- Integration of behavioral therapy with medication regimens
A multidisciplinary approach combines psychiatry, nursing, and psychology expertise to enhance care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 22 therapeutic areas and 15 of 141 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 139 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 45 by active trials.
- 1Hospices Civils De Lyon7active
lock +44 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Hospices Civils De Lyon8trials
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospices Civils De Lyon
lock Showing 1 of 100 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 141 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 4 | Unknown | 2022-02-11 | 2023-11-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.